In the Phase 3 PALISADE trial (NCT05089084) patients are being recruited to investigate the efficacy and safety of ARO-APOC3 in the treatment of adults with familial chylomicronemia syndrome.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
